Statin adjunctive therapy shortens the duration of TB treatment in mice.

ABSTRACT:

Background

The repurposing of existing agents may accelerate TB drug development. Recently, we reported that the lipid-lowering drug simvastatin, when added to the first-line antitubercular regimen, reduces the lung bacillary burden in chronically infected mice.

Objectives

We investigated whether the addition of simvastatin to the first-line regimen (isoniazid/rifampicin/pyrazinamide) shortens the duration of curative TB treatment in mice.

Methods

Mycobacterium tuberculosis-infected THP-1 cells were exposed to simvastatin to determine the effect of statins on the activity of first-line anti-TB drug activity and intracellular rifampicin concentration. Single-dose and steady-state pharmacokinetic studies guided optimized simvastatin dosing in vivo. BALB/c mice were aero

SUBMITTER: Dutta NK 

PROVIDER: S-EPMC5007636 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature